Clinical Trial Update: A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy [Phase 1]

View source ↗

Summary

Phase 1 study evaluating tolerability of escalating doses of BI 771716 in people with geographic atrophy, an advanced form of age-related macular degeneration; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• BI 771716

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Geographic Atrophy | Phase 1 | Status: COMPLETED